PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $32.00

PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective lifted by The Goldman Sachs Group from $18.00 to $32.00 in a report published on Tuesday, Benzinga reports. The Goldman Sachs Group currently has a sell rating on the biopharmaceutical company’s stock. Several other analysts also recently commented on the stock. Citigroup raised their target […]

Related Keywords

United States ,Jeromeb Zeldis ,Matthewb Klein ,Raymond James ,Burney Co ,Citigroup ,Janus Henderson Group ,Morgan Stanley ,Cantor Fitzgerald ,Securities Exchange Commission ,Lazard Asset Management ,Jacobs Levy Equity Management Inc ,Healthcare Of Ontario Pension Plan Trust Fund ,Nasdaq ,Goldman Sachs Group ,Therapeutics Inc ,Free Report ,Get Free Report ,Exchange Commission ,Director Jerome ,Levy Equity Management ,Henderson Group ,Asset Management ,Ontario Pension Plan Trust Fund ,